Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.

MLA

Arbour, Kathryn C., et al. “Twice Weekly Pulse and Daily Continuous-Dose Erlotinib as Initial Treatment for Patients with Epidermal Growth Factor Receptor-Mutant Lung Cancers and Brain Metastases.” Cancer (0008543X), vol. 124, no. 1, Jan. 2018, pp. 105–09. EBSCOhost, https://doi.org/10.1002/cncr.30990.

APA

Arbour, K. C., Kris, M. G., Riely, G. J., Ni, A., Beal, K., Daras, M., Hayes, S. A., Young, R. J., Rodriguez, C. R., Ahn, L., Pao, W., & Yu, H. A. (2018). Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases. Cancer (0008543X), 124(1), 105–109. https://doi.org/10.1002/cncr.30990

Chicago

Arbour, Kathryn C., Mark G. Kris, Gregory J. Riely, Ai Ni, Kathryn Beal, Mariza Daras, Sara A. Hayes, et al. 2018. “Twice Weekly Pulse and Daily Continuous-Dose Erlotinib as Initial Treatment for Patients with Epidermal Growth Factor Receptor-Mutant Lung Cancers and Brain Metastases.” Cancer (0008543X) 124 (1): 105–9. doi:10.1002/cncr.30990.